Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)

被引：0
|
作者：
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
机构：
[1] McGill Univ, Jewish Gen Hosp, Montreal, PQ, Canada
[2] City Hope Natl Med Ctr, Duarte, CA USA
[3] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[4] NYU Langone Hlth, Perlmutter Canc Ctr, New York, NY USA
[5] Univ Pittsburgh, UPMC Hillman Canc Ctr, Pittsburgh, PA USA
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] Brown Univ, Legorreta Canc Ctr, Lifespan Canc Inst, Providence, RI USA
[8] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
[10] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[11] Penn State Univ, Coll Med, Hershey, PA USA
[12] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA
[13] Genentech Inc, South San Francisco, CA USA
[14] F Hoffmann La Roche Ltd, Mississauga, ON, Canada
[15] Univ Colorado, Aurora, CO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7021
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Mosunetuzumab with Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)
    Assouline, Sarit
    Budde, Lihua Elizabeth
    Chavez, Julio C.
    Diefenbach, Catherine S.
    Dorritie, Kathleen Anne
    Ghosh, Nilanjan
    Olszewski, Adam J.
    Lossos, Izidore S.
    Mehta, Amitkumar
    Modi, Dipenkumar
    Naik, Seema
    Smith, Stephen Douglas
    Makadia, Sneha
    Pham, Song
    Wu, Hao
    Batlevi, Connie Lee
    To, Iris
    Wei, Michael C.
    Kamdar, Manali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S461 - S461
  • [2] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M.
    Zenz, T.
    Rosler, W.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 66 - 67
  • [3] Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Sehn, Laurie H.
    Herrera, Alex F.
    Flowers, Christopher R.
    Kamdar, Manali K.
    McMillan, Andrew
    Hertzberg, Mark
    Assouline, Sarit
    Kim, Tae Min
    Kim, Won Seog
    Ozcan, Muhit
    Hirata, Jamie
    Penuel, Elicia
    Paulson, Joseph N.
    Cheng, Ji
    Ku, Grace
    Matasar, Matthew J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 155 - +
  • [4] Polatuzumab vedotin in relapsed/refractory diffuse large B-cell lymphoma
    Dietliker, N.
    Kiesel, H.
    Mueller, R.
    Mueller, A. M.
    Manz, M. G.
    Zenz, T.
    Rosler, W.
    SWISS MEDICAL WEEKLY, 2020, : 21S - 21S
  • [5] Mosunetuzumab Plus Polatuzumab Vedotin Demonstrates a Favorable Safety Profile and Efficacy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma ( LBCL): Primary Analysis of a Phase Ib/II Study
    Budde, L. Elizabeth
    Olszewski, Adam J.
    Assouline, Sarit
    Lossos, Izidore S.
    Diefenbach, Catherine
    Kamdar, Manali
    Ghosh, Nilanjan
    Modi, Dipenkumar
    Sabry, Waleed
    Naik, Seema
    Mehta, Amitkumar
    Nakhoda, Shazia K.
    Smith, Stephen D.
    Dorritie, Kathleen
    Jia, Ting
    Pham, Song
    Huw, Ling-Yuh
    Wu, Hao
    To, Iris
    Wei, Michael C.
    Chavez, Julio C.
    BLOOD, 2023, 142
  • [6] Polatuzumab Vedotin: Honing in on Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Shingleton, Jennifer R.
    Dave, Sandeep S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (02) : 166 - +
  • [7] Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma
    Varma, Gaurav
    Wang, Jacqueline
    Diefenbach, Catherine
    EXPERT REVIEW OF ANTICANCER THERAPY, 2022, 22 (08) : 795 - 803
  • [8] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
    Malecek, Mary-Kate
    Watkins, Marcus P.
    Bartlett, Nancy L.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
  • [9] Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
    Budde, Lihua E.
    Olszewski, Adam J.
    Assouline, Sarit
    Lossos, Izidore S.
    Diefenbach, Catherine
    Kamdar, Manali
    Ghosh, Nilanjan
    Moth, Dipenkumar
    Sabry, Waleed
    Naik, Seema
    Mehta, Amitkumar U.
    Nakhoda, Shazia K.
    Smith, Stephen D.
    Dorritie, Kathleen
    Jia, Ting
    Pham, Song
    Huw, Ling-Yuh
    Jing, Jing
    Wu, Hao
    Ead, Wahib S.
    To, Iris
    Batlevi, Connie Lee
    Wei, Michael C.
    Chavez, Julio C.
    NATURE MEDICINE, 2024, 30 (01) : 229 - +
  • [10] Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: a phase 1b/2 trial
    Lihua E. Budde
    Adam J. Olszewski
    Sarit Assouline
    Izidore S. Lossos
    Catherine Diefenbach
    Manali Kamdar
    Nilanjan Ghosh
    Dipenkumar Modi
    Waleed Sabry
    Seema Naik
    Amitkumar Mehta
    Shazia K. Nakhoda
    Stephen D. Smith
    Kathleen Dorritie
    Ting Jia
    Song Pham
    Ling-Yuh Huw
    Jing Jing
    Hao Wu
    Wahib S. Ead
    Iris To
    Connie Lee Batlevi
    Michael C. Wei
    Julio C. Chavez
    Nature Medicine, 2024, 30 : 229 - 239
12345